ATTRALUS Trademark

Trademark Overview

On Monday, August 10, 2020, a trademark application was filed for ATTRALUS with the United States Patent and Trademark Office. The USPTO has given the ATTRALUS trademark a serial number of 90104221. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, July 30, 2024. This trademark is owned by Aurora Bio, Inc.. The ATTRALUS trademark is filed in the Pharmaceutical Products category with the following description:

Diagnostic agents, preparations and substances for medical purposes; diagnostic agents for medical purposes, namely, diagnostic scanning agents for in vivo use for detection and monitoring of systemic amyloid diseases, such as transthyretin amyloidosis, Light Chain Amyloidosis and LECT2 Amyloidosis; diagnostic radiopharmaceutical preparations for clinical, medical and research use in the field of systemic amyloid disease; radioactive pharmaceutical preparations and non-radioactive reagents for producing radiopharmaceuticals for in vivo diagnostic or therapeutic use; pharmaceutical preparations for use in diagnosis and treatment of systemic amyloid disease; all of the aforesaid for human use
attralus

General Information

Serial Number90104221
Word MarkATTRALUS
Filing DateMonday, August 10, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, July 30, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 12, 2021

Trademark Statements

Goods and ServicesDiagnostic agents, preparations and substances for medical purposes; diagnostic agents for medical purposes, namely, diagnostic scanning agents for in vivo use for detection and monitoring of systemic amyloid diseases, such as transthyretin amyloidosis, Light Chain Amyloidosis and LECT2 Amyloidosis; diagnostic radiopharmaceutical preparations for clinical, medical and research use in the field of systemic amyloid disease; radioactive pharmaceutical preparations and non-radioactive reagents for producing radiopharmaceuticals for in vivo diagnostic or therapeutic use; pharmaceutical preparations for use in diagnosis and treatment of systemic amyloid disease; all of the aforesaid for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 10, 2020
Primary Code005
First Use Anywhere DateTuesday, July 25, 2023
First Use In Commerce DateTuesday, July 25, 2023

Trademark Owner History

Party NameATTRALUS, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressBurlingame, CA 94010
Party NameAurora Bio, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameAurora Bio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events

Event DateEvent Description
Thursday, August 13, 2020NEW APPLICATION ENTERED
Thursday, September 10, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 3, 2020ASSIGNED TO EXAMINER
Thursday, December 3, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 23, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 12, 2021PUBLISHED FOR OPPOSITION
Tuesday, January 12, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 9, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, September 1, 2021AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Thursday, September 9, 2021SOU TEAS EXTENSION RECEIVED
Thursday, September 9, 2021TEAS REQUEST TO DIVIDE RECEIVED
Thursday, September 9, 2021DIVISIONAL REQUEST RECEIVED
Thursday, September 9, 2021SOU EXTENSION 1 FILED
Friday, September 17, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, September 17, 2021DIVISIONAL PROCESSING COMPLETE
Friday, September 17, 2021SOU EXTENSION 1 GRANTED
Saturday, September 18, 2021CORRECTED NOA E-MAILED
Saturday, September 18, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 2, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, March 2, 2022SOU EXTENSION 2 FILED
Wednesday, March 2, 2022SOU EXTENSION 2 GRANTED
Friday, March 4, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 30, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, August 30, 2022SOU EXTENSION 3 FILED
Tuesday, August 30, 2022SOU EXTENSION 3 GRANTED
Thursday, September 1, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 1, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, March 1, 2023SOU EXTENSION 4 FILED
Wednesday, March 1, 2023SOU EXTENSION 4 GRANTED
Friday, March 3, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 17, 2023SOU TEAS EXTENSION RECEIVED
Thursday, August 17, 2023SOU EXTENSION 5 FILED
Thursday, September 14, 2023SOU EXTENSION 5 GRANTED
Friday, September 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 8, 2024TEAS STATEMENT OF USE RECEIVED
Friday, March 8, 2024USE AMENDMENT FILED
Monday, March 11, 2024STATEMENT OF USE PROCESSING COMPLETE
Monday, April 15, 2024NON-FINAL ACTION E-MAILED
Monday, April 15, 2024SU - NON-FINAL ACTION - WRITTEN
Monday, April 15, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 30, 2024ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, July 30, 2024ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND

Related Keywords

attralus diagnostic preparations systemic amyloid amyloidosis medical agents pharmaceutical disease purposes